KRAS and colorectal carcinoma: To study the functional relationship between CD166 and KRAS exon 2 mutations, we propose to use RNA interference–mediated knockdown of CD166 to compare the status of KRAS exon 2 mutations in CD166-positive and negative cells and examine the invasive potential of the CRC cells.